COMMUNIQUÉS West-GlobeNewswire

-
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
02/01/2019 -
Holding(s) in Company
02/01/2019 -
ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
02/01/2019 -
ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
02/01/2019 -
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/01/2019 -
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe
31/12/2018 -
U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process
31/12/2018 -
Green Growth Brands Reaffirms Commitment to Takeover Aphria Inc.
31/12/2018 -
Merus annonce les résultats financiers du troisième trimestre 2018 et fait le point sur son activité
31/12/2018 -
Alder BioPharmaceuticals® to Present at the 37th Annual J.P. Morgan Healthcare Conference
31/12/2018 -
CLS Holdings USA, Inc. Issues Year End Review Letter
31/12/2018 -
Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
31/12/2018 -
Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
31/12/2018 -
Geron Announces New Board Leadership Structure
31/12/2018 -
Peter D. Meldrum (1947-2018)
31/12/2018 -
Chief Medical Director Kari Syrjänen will retire from Biohit Oyj
31/12/2018 -
GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
31/12/2018 -
Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.
31/12/2018 -
Eve & Co Announces First Shipment of Dried Cannabis Product and Files Financial Results for the Three and Twelve Month Periods Ended October 31, 2018
31/12/2018
Pages